Published Research
CLINUVEL has conducted over 15 trials of SCENESSE® (afamelanotide 16mg) involving over 900 patients, of which the published research can be purchased online.
Below is a selection of published research on SCENESSE®. These links direct you to sites outside of the control of CLINUVEL and are not produced or endorsed by CLINUVEL.
Sancar, F. (2019). First Treatment for Rare Photosensitivity. Jama. 2019;322(19):1854-1854.
Over 200 articles have been published on afamelanotide (chemical name [Nle4, D-Phe7]α-MSH or NDP-MSH).